A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Pegargiminase (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
Most Recent Events
- 30 Nov 2023 Planned number of patients changed from 40 to 60, according to a Polaris Group media release.
- 30 Nov 2023 According to a Polaris Group media release, first patient has been successfully dosed in this study.
- 30 Nov 2023 Status changed from not yet recruiting to recruiting, according to a Polaris Group media release.